We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: STEMI
MedXY News
EnglishTag

STEMI

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Bivalirudin Versus Heparin in Primary PCI for STEMI: Efficacy Across Low and High Bleeding Risk Patients – Insights from the BRIGHT-4 Trial
Cardiologybleeding riskSTEMI

Bivalirudin Versus Heparin in Primary PCI for STEMI: Efficacy Across Low and High Bleeding Risk Patients – Insights from the BRIGHT-4 Trial

By MedXY|Sep 17, 2026

The BRIGHT-4 trial demonstrates that bivalirudin with prolonged infusion reduces 30-day mortality and major bleeding compared to heparin in STEMI patients undergoing radial primary PCI, benefiting both low and higher bleeding risk groups.

Intravenous Nicorandil in STEMI Patients Undergoing Primary PCI: Insights from the CLEAN Randomized Clinical Trial and Broader Evidence
CardiologySTEMI
primary PCI

Intravenous Nicorandil in STEMI Patients Undergoing Primary PCI: Insights from the CLEAN Randomized Clinical Trial and Broader Evidence

By MedXY|Aug 17, 2026

The CLEAN trial shows intravenous nicorandil adjunctive to primary PCI does not significantly improve 12-month clinical outcomes in STEMI. Evidence suggests microvascular benefits but no consistent long-term mortality or infarct size reduct

STEMI and NSTEMI Are Not the Same in Type 1 Diabetes: Finnish Cohort Reveals Distinct Risk Patterns
Cardiologymyocardial infarctionNSTEMI

STEMI and NSTEMI Are Not the Same in Type 1 Diabetes: Finnish Cohort Reveals Distinct Risk Patterns

By MedXY|Apr 1, 2026

In Finnish adults with type 1 diabetes, STEMI and NSTEMI showed distinct incidence trends and risk profiles. NSTEMI was more common overall and linked to dyslipidemia and advanced microvascular disease, whereas impaired eGFR tracked more wi

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks
CardiologyCardiologyRevascularization

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks

By MedXY|Feb 8, 2026

An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial
CardiologyAntiplatelet TherapyCardiology

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

By MedXY|Jan 17, 2026

The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar

Mental Health Labels Linked to Critical Delays and Doubled Five-Year Mortality in STEMI Care
Cardiologyclinical outcomeshealth disparities

Mental Health Labels Linked to Critical Delays and Doubled Five-Year Mortality in STEMI Care

By MedXY|Jan 3, 2026

A prospective study reveals that patients with mental health conditions face significant delays in STEMI diagnosis, resulting in larger infarct sizes and a twofold increase in five-year cardiovascular mortality compared to those without suc

The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality
CardiologyCardiologyemergency medicine

The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality

By MedXY|Jan 3, 2026

A 20-year analysis of 89,155 patients from the SWEDEHEART registry confirms that pre-hospital delay independently predicts short- and long-term mortality. Despite advances in reperfusion, women, elderly patients, and those with diabetes con

Post-PCI Troponin Kinetics Reveal Hemorrhagic Transformation as a Critical Driver of In-Hospital Mortality in STEMI
CardiologyReperfusion InjurySTEMI

Post-PCI Troponin Kinetics Reveal Hemorrhagic Transformation as a Critical Driver of In-Hospital Mortality in STEMI

By MedXY|Dec 31, 2025

A multicenter study identifies high-sensitivity troponin I kinetics as a diagnostic marker for hemorrhagic myocardial infarction, linking this reperfusion injury to a nearly threefold increase in the risk of in-hospital mortality following

Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS
Cardiologycardiogenic shockImpella

Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS

By MedXY|Dec 31, 2025

This study validates the DanGer Shock trial criteria in a real-world registry, demonstrating that patients matching the trial’s profile have significantly better survival outcomes when treated with microaxial flow pumps compared to th

Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock
Cardiologycardiogenic shockhemodynamics

Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock

By MedXY|Dec 31, 2025

Recent substudies from the DanGer Shock trial demonstrate that microaxial flow pumps significantly improve hemodynamics, accelerate lactate clearance, and reduce vasopressor needs in STEMI-related cardiogenic shock, though sex-specific outc

Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial
CardiologyCardiologyLDL-C

Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial

By MedXY|Dec 24, 2025

This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of

Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding
CardiologySTEMI

Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding

By MedXY|Nov 13, 2025

In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with mor

Immediate vs Deferred PCI for Nonculprit Lesions in STEMI: Insights from the iMODERN Trial
CardiologyCardiac Magnetic ResonanceMultivessel Disease

Immediate vs Deferred PCI for Nonculprit Lesions in STEMI: Insights from the iMODERN Trial

By MedXY|Oct 31, 2025

The iMODERN trial demonstrates that immediate iFR-guided PCI of nonculprit lesions in STEMI patients offers no significant benefit over deferred stress MRI-guided PCI regarding major cardiac events at 3 years.

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients
Cardiologyacute coronary syndromeAspirin

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY|Oct 9, 2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Immediate Versus Staged Complete Revascularisation in STEMI with Multivessel Disease: Insights from the OPTION-STEMI Trial
CardiologyMultivessel DiseasePCI

Immediate Versus Staged Complete Revascularisation in STEMI with Multivessel Disease: Insights from the OPTION-STEMI Trial

By MedXY|Oct 8, 2025

The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings
Cardiologyheart failurePercutaneous Coronary Intervention

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

By MedXY|Oct 3, 2025

The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI
CardiologyFFRmajor adverse cardiovascular events

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY|Oct 3, 2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque chara

Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial
Cardiologydrug-eluting stentsneoatherosclerosis

Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial

By MedXY|Oct 2, 2025

The CONNECT trial demonstrates no significant difference in neoatherosclerosis rates 3 years post-STEMI between biodegradable and durable polymer everolimus-eluting stents, challenging assumptions about biodegradable polymers’ superio

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities